2016 Webinars
Collapse Bacterial and Fungal Typing by Sequence-based Methods

Description:

This presentation discusses current methods used to identify bacteria by 16S rRNA gene sequencing and fungi by use of the ITS (Internal Transcribed Spacers) and D1/D2 regions, including both technical and bioinformatic analyses. Additional content covers use of these methods to identify pathogens in primary samples, example cases and clinical reporting, potential application of next generation sequencing (NGS)-based methods, and considerations for labs developing and implemeting these assays.

Speaker: Lynn Bry, MD, PhD

Host: Colleen Kraft, MD

Duration: 40 min.

Level of Instruction: Basic

 

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Bry Presentation
Original Course Date: May 27, 2016
MORE INFOMORE INFO Bacterial and Fungal Typing by Sequence-based Methods
Collapse Promises and Pitfalls of Circulating Tumor DNA

In oncology, there are a variety of potential clinical applications for a minimally invasive blood test for DNA released from tumor cells. Such applications include detecting early stage disease, tracking response to therapy, prompt identification of disease relapse or recurrence, and recognition of clonal evolution.  Numerous small-scale studies have demonstrated that quantitation of mutations in circulating tumor DNA (ctDNA) is feasible from the blood of cancer patients. The increased adoption of targeted cancer therapies underscores the need to augment invasive tissue biopsies with alternative detection methods that rapidly monitor treatment response. Although most studies have been proof of principle, ctDNA methods hold great promise in cancer diagnostics.

 

Speaker: Christina Lockwood, PhD, DABCC, FACB

Duration: 1.0 hr

Level of Instruction: Basic

 

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Streaming
Original Course Date: June 09, 2016
MORE INFOMORE INFO Promises and Pitfalls of Circulating Tumor DNA
Collapse Structural Variant Discovery and Considerations for the Clinical Laboratory

Description:

In this webinar, Dr. Zehir talks about the structural variation in the genome and the ways it relates to disease formation and treatment. He focuses on the different strategies to detect and visualize them using next-generation sequencing technologies for the clinical laboratory with a focus in cancer. 


Speaker: Ahmet Zehir, PhD

Host: N. Sertac Kip, MD, PhD

Duration: 40 min.

Level of Instruction: Basic

 

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Zehir Presentation
Original Course Date: September 09, 2016
MORE INFOMORE INFO Structural Variant Discovery and Considerations for the Clinical Laboratory
Collapse The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer

Recent definitions for clinical utility of molecular tests focus on whether a test result will alter treatment. This definition neglects other uses of molecular testing to diagnose disease, manage symptoms, prognosticate or predict future disease. The fullest realization of precision medicine will require embracing all aspects of clinical utility. This three-part webinar series, supported by AMP, presents the discussions of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility (FEND) working group, and its resulting publication, “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology” (Joseph L, et al. J Mol Diagn. 2016;18[5]:605–619).

 

Part 1 - An Overview of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility

Speakers: Loren Joseph, MD; Elaine Lyon, PhD

Host: Roger Klein, MD, JD

 

Part 2 - AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Oncology Cases

Speakers: Pranil Chandra, DO, FCAP, FASP; Rajyasree Emmadi, MD, FCAP

Host: Loren Joseph, MD

 

Part 3: AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Inherited Conditions

Speakers: Stephanie Hallam, PhD, FACMG, MBA; Victoria Pratt, PhD, FACMG

Host: Elaine Lyon, PhD

Practice Guideline Available Here

Total Duration: 3 hr

 

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Streaming
Original Course Date: September 28, 2016
MORE INFOMORE INFO The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer
Collapse The Who, What, and When of the PAMA Final Rule

Just released are the final regulations of The Protecting Access to Medicare Act (PAMA) Section 216. PAMA significantly revises the Medicare payment system for clinical diagnostic laboratory tests by requiring that Medicare payment for clinical laboratories be based on the weighted median of private payer rates along with a number of other provisions.

 

Please note that details on this final rule are still being elucidated and additional specifics are expected to be introduced by CMS in the coming months. Therefore, this webcast is just the first AMP educational event on PAMA implementation. The AMP Economic Affairs Committee will continue to update membership as details emerge and the committee is organizing a session on PAMA at this year's annual meeting.

 

Speaker: Erika Miller, JD

Host: Tara Burke, PhD

 

Duration: 1 hr

Level of Instruction: Basic

Recorded: June 30, 2016

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

 

Formats Available: Streaming
Original Course Date: June 30, 2016
On-Demand Release Date: Available Now
MORE INFOMORE INFO The Who, What, and When of the PAMA Final Rule
Collapse Zika Virus: Diagnostic Testing and Front-Line Management

A Collaborative Educational Event Presented by AMP, PASCV and APHL

 

Zika in Latin America: Clinical Aspects by Dr. Cecilia Perret

Dr. Perret reviews the epidemiology of the Zika outbreak in Latin America, some clinical aspects, evidence of a Zika infection, and its complications (congenital disease and Guillain Barre Syndrome). In addition, she will discuss the local response to a series of travelers infected with Zika, including a pregnant woman and a sexually transmitted infection.

Zika Virus Diagnostics by Dr. Benjamin Pinsky

Zika virus (ZIKV) is an Aedes mosquito-borne flavivirus that emerged in Brazil in 2015 and then rapidly spread throughout the tropical and subtropical Americas. Based on clinical criteria alone, ZIKV cannot be reliably distinguished from infections with other pathogens that cause an undifferentiated systemic febrile illness, including infections with two common arboviruses, dengue virus and chikungunya virus. This presentation details the methods that are available to diagnose ZIKV infection.

 

Duration: 1.0hr.

Level of Instruction: Intermediate

 

All sales are final. No refunds will be issued.

Note:

Members of AMP can access this webinar at no cost. Join the AMP Family!

Members of PASCV can access this webinar at no cost from PASCV (www.pascv.org).

Members of APHL may be able to access this webinar from APHL (www.aphl.org).

 

Formats Available: Streaming
Original Course Date: April 29, 2016
MORE INFOMORE INFO Zika Virus: Diagnostic Testing and Front-Line Management